Question Bank › The open question just closed

The open question just closed

The open question just closed: management treats a doubt that used to hang over the business as now answered, and names

Calls Tested
467
Answered YES
7
Hit Rate
1.5%
rare by design

Regeneron Pharmaceuticals, Inc. (REGN) — this company's answers

NO on the Q4 2022 call 2023-02-03 C
The model's full reasoning — Q4 2022 call → NOWe need answer YES/NO. Need analyze transcript for specific doubt/open question acknowledged by management, now resolved favorably with evidence. Let's inspect. Management remarks: Len: "strong fourth quarter performance kept remarkable year... highlighted by significant achievements... revenue increased 14%... excluding REGEN-COV... commercial strength and diversity." Pipeline advances. "Briefly reflecting on 2022, we ended the year with three strategic imperatives that we felt we had to accomplish in order to position the company for long-term growth. First, we had to fortify the medium and long-term outlook for our retinal franchise. Based on positive results... aflibercept 8 milligrams has potential... Second, we needed to maintain and grow DUPIXENT leadership... 2022 turned out to be phenomenal... Third, we wanted to make significant progress towards becoming a leader in immunooncology and 2022 turned out to be crucial. Key to this long-term goal was requiring Sanofi’s share of global rights to Libtayo... necessary step towards realizing full clinical and commercial potential... It also enables us to unlock combination opportunities..." This is more about imperatives accomplished, not necessarily a doubt. George: "In ophthalmology, we presented pivotal positive results... These trials showed... extended dosing intervals... without compromising... These are truly unprecedented and potentially game-changing results who have not – which have not been achieved using any other anti-VEGF agents." Not a doubt. Dupixent: approvals. "In 2023, we are looking forward to initial results of BOREAS... COPD... passed interim futility analysis in 2020, encouraging event... We are looking forward to readout... expected first half '23." This is still open, not resolved. Oncology: "2022 was an important year... Libtayo approved... Libtayo is also emerging as essential backbone... several programs... starting to yield encouraging data." "we have recently shown positive data from a second confirmatory cohort... and reported encouraging results... These initial results suggest... potentially best-in-class profile... And we are advancing broad pivotal programs..." "Other notable Libtayo combination used from this year was the early but very encouraging data with our PSMA by CD28 costimulatory bispecific...

← Back to the full REGN analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management identify a SPECIFIC DOUBT OR OPEN QUESTION that until recently hung over the business — something that was genuinely uncertain or unproven about the company in the recent past — and convey that this question has NOW BEEN ANSWERED IN THE COMPANY'S FAVOR, pointing to real, recent evidence from the business itself as what settled it? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent shift: something that used to be an "if" for this company is now discussed as settled fact, and management can say what settled it. The doubt may take many forms, and any genuine version counts — for example: whether customers would actually buy, adopt, renew, or return; whether a product, technology, process, or service would work at real-world scale outside the lab or pilot; whether the economics of the model could ever be attractive; whether a new market, channel, geography, or customer type would accept the company; whether a ramp, launch, transition, integration, or turnaround would actually take hold; whether demand was a one-time spike or durable; whether the company could operate profitably, fund itself, or stand on its own. Management should (a) acknowledge — directly or plainly in substance — that this was a real open question or source of skepticism until recently, whether raised by investors, customers, or the company itself; (b) state that the question is now resolved in the company's favor, speaking about it in the settled, matter-of-fact register of something proven rather than argued; and (c) ground the resolution in concrete recent evidence from the business — actual repeat behavior, real performance in the field, sustained results across customers or periods, completed proof in live operation, or other observed outcomes from the recent past — rather than in confidence, projections, or plans. It strengthens a YES when management describes what the company is now doing differently because the question is closed — planning, investing, or committing on the assumption of the answer. Answer NO if no prior doubt or open question about the business is ever acknowledged — a strong company reporting another good quarter in the usual confident way is not this phenomenon. NO if the doubt is described as still open, only partially answered, or expected to be resolved by future results, trials, or milestones. NO if the claimed resolution rests on management's confidence, belief, or optimism rather than on named recent evidence from the business. NO if the "proof" cited is only a single quarter's financial beat with no underlying business evidence described. NO if management is still actively arguing, defending, or pleading the very point it claims is settled, so the register remains persuasion rather than settled fact. NO if the resolved question is trivial or peripheral to the company rather than a doubt that mattered to what the company could become. NO if the idea appears only in an analyst's question or characterization that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
ALL The Allstate Corporation Q3 2023 2023-11-02 C+
CUE Cue Biopharma, Inc. Q3 2022 2022-11-14 D
EGY VAALCO Energy, Inc. Q2 2021 2021-08-12 B
AMC AMC Entertainment Holdings, Inc. Q2 2021 2021-08-09 D
IRT Independence Realty Trust, Inc. Q2 2018 2018-08-02 B
BCOV Brightcove Inc. Q1 2018 2018-04-26 B+
LBTYK Liberty Global's Q1 2016 2016-05-10 C+

How the model reasoned

IRT · Q2 2018 → YESThe question is: Does management identify a SPECIFIC DOUBT OR OPEN QUESTION that until recently hung over the business, and convey that this question has NOW BEEN ANSWERED IN THE COMPANY'S FAVOR with ...YES Management explicitly frames the value-add program as having resolved a prior open question about whether renovations would deliver sustainable long-term growth after short-term disruption. Scott notes the Q2 results "confirmed our confidence and excitement about our ability to generate outsized returns from our value-add program." Farrell directly acknowledges the temporary occupancy impact but states that "our thesis that the short-term pain will yield long-term growth is validated by these returns," citing concrete recent evidence: renovated units generating $186/month rent premiums (21% ROI), a backlog of ~100 pre-leased units, and leasing faster than completion.
BCOV · Q1 2018 → YESThe question is: Does management identify a SPECIFIC DOUBT OR OPEN QUESTION that until recently hung over the business, and convey that this question has NOW BEEN ANSWERED IN THE COMPANY'S FAVOR, poin...YES The transcript shows management explicitly identifying the commodity pricing reset in the media business as a prior open question that had been hanging over retention performance. Andrew Feinberg directly ties the 103% recurring dollar retention rate to “our success and working through the final quarter of our commodity pricing reset,” then states they have “now completed that process” and have “a healthier stickier and higher value added revenue base.” Kevin Rhodes reinforces that they are “now through the commodity pricing reset” and expect sustained 91-94% retention going forward.
EGY · Q2 2021 → YESThe question is: Does management identify a SPECIFIC DOUBT OR OPEN QUESTION that until recently hung over the business, and convey that this question has NOW BEEN ANSWERED IN THE COMPANY'S FAVOR, poin...YES George Maxwell directly acknowledges that the feasibility of reaching the Venus discovery zone from the shelf (rather than deeper water) was a genuine open question that had to be resolved before proceeding: “we had to try and determine was it possible to meet the targeted zones from the shelves… Having established that, that was possible.

More from the question bank

Operating in the future tenseSold before it existsDisproportional responseAnswers go deeper than the scriptSequential re-ratingBreak from their own historyAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.